What were the main drivers of Stryker's revenue growth in 2005?

Stryker's revenue growth in 2005 was driven by a combination of factors including increased unit volume and product mix, higher selling prices, and strategic acquisitions. Specifically, strong performance in reconstructive, trauma, and spinal implant systems within the Orthopaedic Implants segment, along with robust sales of surgical equipment and digital imaging systems in the MedSurg Equipment segment, contributed significantly to the 14% overall sales increase.

How did the repatriation of foreign earnings impact Stryker's financial position?

In the fourth quarter of 2005, Stryker repatriated $722 million of foreign earnings under the American Jobs Creation Act. This event provided the company with additional domestic capital that has been invested according to an approved reinvestment plan. While it incurred related income tax expenses, it enhanced the company's financial flexibility for future investments and operations.

What is Stryker's strategy regarding acquisitions and research and development?

Stryker's strategy involves both organic growth through significant investment in R&D and inorganic growth via strategic acquisitions. In 2005, the company acquired PlasmaSol Corp. to enhance its sterilization equipment capabilities and eTrauma.com Corp. to expand its digital imaging offerings. R&D spending increased to 5.7% of sales, indicating a strong focus on developing new products and technologies to complement its existing lines and maintain a competitive edge in the medical technology market.

What are the key risks and challenges mentioned in the report?

The report outlines several key risks, including the potential negative impact of stricter pricing guidelines in the orthopaedics industry, the risk of obsolescence and associated inventory write-downs due to rapid market changes, and the challenge of capitalizing on R&D spending, which could be hampered by regulatory delays or patent disputes. Additionally, potential product liability claims, unfavorable legal outcomes, and the impact of economic or political developments in international markets are noted as significant risks.

SYK 10-K FY2005 Annual Report — Revenue, Net Income, EPS

Summary

Stryker Corporation's 2005 10-K report highlights a strong year of growth, with net sales increasing 14% to $4.87 billion, driven by robust performance in both its Orthopaedic Implants and MedSurg Equipment segments. The company completed a significant repatriation of $722 million in foreign earnings, leveraging the American Jobs Creation Act, which will be reinvested domestically. Strategic acquisitions played a key role, with the integration of PlasmaSol Corp. and eTrauma.com Corp. bolstering Stryker's product offerings in sterilization equipment and digital imaging, respectively. The company also made substantial investments in research and development, increasing R&D spending to 5.7% of sales, underscoring its commitment to innovation. Looking ahead, Stryker projected continued growth and earnings per share expansion in 2006, signaling confidence in its market position and product pipeline.

Key Highlights

1Net sales grew 14% year-over-year to $4.87 billion in 2005, demonstrating strong market demand.
2The company repatriated $722 million in foreign earnings under the American Jobs Creation Act, enhancing its domestic capital resources.
3Two strategic acquisitions, PlasmaSol Corp. and eTrauma.com Corp., were completed to expand product portfolios.
4Research and development expenses increased to 5.7% of sales, reflecting continued investment in innovation and new product development.
5The Orthopaedic Implants segment saw an 11% sales increase, with notable growth in knee and spinal implant systems.
6The MedSurg Equipment segment experienced a significant 21% sales increase, driven by surgical equipment and digital imaging systems.
7Stryker provided an optimistic outlook for 2006, projecting a 11%-14% increase in net sales and a 21% rise in diluted EPS.

STRYKER CORP Annual Report, Year Ended Dec 31, 2005

Summary

Key Highlights

Frequently Asked Questions